224 related articles for article (PubMed ID: 15739617)
1. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus.
Horscroft N; Lai VC; Cheney W; Yao N; Wu JZ; Hong Z; Zhong W
Antivir Chem Chemother; 2005; 16(1):1-12. PubMed ID: 15739617
[TBL] [Abstract][Full Text] [Related]
2. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication.
Kim SS; Peng LF; Lin W; Choe WH; Sakamoto N; Kato N; Ikeda M; Schreiber SL; Chung RT
Gastroenterology; 2007 Jan; 132(1):311-20. PubMed ID: 17241881
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
4. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
5. Anti-hepatitis C virus RdRp activity and replication of novel anilinobenzothiazole derivatives.
Peng HK; Chen WC; Lin YT; Tseng CK; Yang SY; Tzeng CC; Lee JC; Yang SC
Antiviral Res; 2013 Oct; 100(1):269-75. PubMed ID: 23994188
[TBL] [Abstract][Full Text] [Related]
6. High-throughput screening of HCV RNA replication inhibitors by means of a reporter replicon system.
Hao W; Duggal R
Methods Mol Biol; 2009; 510():243-50. PubMed ID: 19009266
[TBL] [Abstract][Full Text] [Related]
7. Non-nucleoside inhibitors of the HCV polymerase.
Sarisky RT
J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
[TBL] [Abstract][Full Text] [Related]
10. In vitro replication models for the hepatitis C virus.
Sheehy P; Mullan B; Moreau I; Kenny-Walsh E; Shanahan F; Scallan M; Fanning LJ
J Viral Hepat; 2007 Jan; 14(1):2-10. PubMed ID: 17212638
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of compound activity against hepatitis C virus in replicon systems.
Yang G; Huang M
Curr Protoc Pharmacol; 2010 Sep; Chapter 13():Unit 13B.1. PubMed ID: 22294366
[TBL] [Abstract][Full Text] [Related]
12. [Current approaches for developing new anti-HCV agents and analyses of HCV replication using anti-HCV agents].
Watashi K; Shimotohno K
Uirusu; 2005 Jun; 55(1):105-10. PubMed ID: 16308536
[TBL] [Abstract][Full Text] [Related]
13. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
[TBL] [Abstract][Full Text] [Related]
14. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties.
Olsen DB; Eldrup AB; Bartholomew L; Bhat B; Bosserman MR; Ceccacci A; Colwell LF; Fay JF; Flores OA; Getty KL; Grobler JA; LaFemina RL; Markel EJ; Migliaccio G; Prhavc M; Stahlhut MW; Tomassini JE; MacCoss M; Hazuda DJ; Carroll SS
Antimicrob Agents Chemother; 2004 Oct; 48(10):3944-53. PubMed ID: 15388457
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha.
Tanabe Y; Sakamoto N; Enomoto N; Kurosaki M; Ueda E; Maekawa S; Yamashiro T; Nakagawa M; Chen CH; Kanazawa N; Kakinuma S; Watanabe M
J Infect Dis; 2004 Apr; 189(7):1129-39. PubMed ID: 15031779
[TBL] [Abstract][Full Text] [Related]
16. 2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.
Klumpp K; Kalayanov G; Ma H; Le Pogam S; Leveque V; Jiang WR; Inocencio N; De Witte A; Rajyaguru S; Tai E; Chanda S; Irwin MR; Sund C; Winqist A; Maltseva T; Eriksson S; Usova E; Smith M; Alker A; Najera I; Cammack N; Martin JA; Johansson NG; Smith DB
J Biol Chem; 2008 Jan; 283(4):2167-75. PubMed ID: 18003608
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus cell culture replication systems: their potential use for the development of antiviral therapies.
Randall G; Rice CM
Curr Opin Infect Dis; 2001 Dec; 14(6):743-7. PubMed ID: 11964894
[TBL] [Abstract][Full Text] [Related]
18. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
19. 3-Amino-2(5H)furanones as inhibitors of subgenomic hepatitis C virus RNA replication.
Iannazzo D; Piperno A; Romeo G; Romeo R; Chiacchio U; Rescifina A; Balestrieri E; Macchi B; Mastino A; Cortese R
Bioorg Med Chem; 2008 Nov; 16(21):9610-5. PubMed ID: 18835180
[TBL] [Abstract][Full Text] [Related]
20. HCV research and anti-HCV drug discovery: toward the next generation.
Wakita T
Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
